Regulus Therapeutics said this week that it has priced the public offering of 4.5 million shares of its common stock at $9.50 each.
As of midday Wednesday, Regulus’ stock was trading around $10.05 a share.
The company anticipates grossing $42.8 million from the offering, which is set to close around July 22. The underwriters of the offering have also been granted an option to purchase an additional 675,000 shares to cover overallotments.